(Measles, mumps and rubella vaccine(Merck Sharp & Dohme)) - 在研适应症：麻疹，腮腺炎，风疹_专利_临床

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗

别名

M-M-RVAXPRO、MMR vaccine、Measles, Mumps, and Rubella Virus Vaccine, Live (Merck & Co)

+ [3]

靶点-

作用机制

免疫刺激剂

治疗领域

感染口颌疾病其他疾病

在研适应症

麻疹腮腺炎风疹

非在研适应症

水痘

原研机构

Merck Sharp & Dohme Corp.

在研机构

Merck Sharp & Dohme BV

Merck & Co., Inc.

非在研机构

Merck Sharp & Dohme Corp.

最高研发阶段批准上市

首次获批日期

美国 (1971-04-22),

麻疹腮腺炎风疹

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

关联

38

项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的临床试验

CTRI/2024/02/062715 / Not yet recruiting临床2期IIT

Comparative analysis of efficacy between homologous autoimplantation therapy and intralesional MMR vaccine in the treatment of viral warts. - MAVW

开始日期2024-02-15

申办/合作机构-

NCT05894395 / Recruiting临床3期IIT

A Cross-Sectional and Open Pre-Post Interventional Study Evaluating Circulating and Mucosal Humoral and Cell-Mediated Immunity Following Measles, Mumps and Rubella (MMR) Vaccination in Adults

The purpose of this study is to investigate the immunity of persons fully vaccinated against measles, mumps and rubella and to examine the course of immunity after booster vaccination.

开始日期2023-12-01

申办/合作机构

University of Zurich

[+1]

CTRI/2023/05/053120 / Active, not recruiting临床3期

A Phase III, open label, prospective, multicenter, label expansion study to evaluate safety and immunogenicity of Inactivated Japanese Encephalitis Vaccine (JEEV™) in 49-70 years old adults and in the healthy 9-12 months old infants either alone or when co-administered with a licensed MMR vaccine at 9 months of age. - None

开始日期2023-06-12

申办/合作机构

Biological E. Ltd.

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的临床结果

登录后查看更多信息

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的转化医学

登录后查看更多信息

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的专利（医药）

登录后查看更多信息

363

项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的文献（医药）

2024-02-01·EClinicalMedicine

Immunogenicity and reactogenicity following MMR vaccination in 5-7-month-old infants: a double-blind placebo-controlled randomized clinical trial in 6540 Danish infants.

Article

作者: Dorthe Maria Vittrup ; Andreas Jensen ; Jesper Kiehn Sørensen ; Anne Cathrine Zimakoff ; Michelle Malon ; Salma Charabi ; Marie Ryberg Johansen ; Eric A F Simões ; Nikolai Søren Kirkby ; Søren Buus ; Jannet Svensson ; Lone Graff Stensballe

Background:

Measles is a highly contagious viral disease. Vaccinated mothers transfer fewer antibodies during pregnancy, resulting in shortened infant immunity. Earlier primary vaccination might avert the gap in protection.

Methods:

Healthy 5-7-month-old Danish infants were assigned in a 1:1 ratio to M-M-RVaxPro or placebo (solvent) in a double-blind, randomized trial between April 15, 2019 and November 1, 2021 (ClinicalTrials.govNCT03780179, EudraCT 2016-001901-18). Eligibility criteria were birth weight >1000 g and gestational age ≥32 weeks.Immunogenicity was measured by plaque reduction neutralization test (PRNT) and IgG ELISA before intervention, four weeks after intervention and routine MMR. Reactogenicity data were collected for six weeks and measured by hazard ratios (HR).

Findings:

647 and 6540 infants participated in the immunogenicity and reactogenicity study, respectively; 87% and 99% completed follow-up. After early MMR, seroprotection rates (SPRs) were 47% (13%) in measles PRNT; 28% (2%), 57% (8%) in mumps and rubella IgG (placebo). For measles PRNT, geometric mean ratio was 4.3 (95% CI: 3.4-5.3) between randomization groups after intervention and 1.5 (95% CI: 1.3-1.9) after routine MMR.Reactogenicity was independent of randomization (HR, 1.0; 95% CI: 0.9-1.1). Severe adverse events occurred in 25 infants (HR, 1.8; 95% CI: 0.8-4.0); none deemed vaccine related.

Interpretation:

Early MMR elicited low SPRs but did not negatively impact short-term responses to a subsequent MMR. MMR at 5-7 months was safe and not associated with higher rates of reactogenicity than placebo.

Funding:

Innovation Fund Denmark.

2023-10-02·JAMA network open

Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients.

Article

作者: Amy G Feldman ; Brenda L Beaty ; Jose A Ferrolino ; Gabriela Maron ; Hillary K Weidner ; Saira A Ali ; Leandra Bitterfeld ; Mary Alice Boulware ; Kathleen M Campbell ; Emily Carr ; Shelley Chapman ; Yeh-Chung Chang ; Ryan Cunningham ; Ronald H Dallas ; Keerti L Dantuluri ; Bryanna N Domenick ; Noelle H Ebel ; Scott Elisofon ; Rima Fawaz ; Marc Foca ; Hayley A Gans ; Vani V Gopalareddy ; Cindy Gu ; Nitika A Gupta ; Katherine Harmann ; Jessica Hollenbeck ; Anna R Huppler ; Catalina Jaramillo ; Nagraj Kasi ; Nanda Kerkar ; Stacee Lerret ; Steven J Lobritto ; Maclovio J Lopez ; Elizabeth Marini ; Alisha Mavis ; Sonia Mehra ; Lynnette Moats ; Sindhu Mohandas ; Flor M Munoz ; Krupa R Mysore ; Ceren Onsan ; Nadia Ovchinsky ; Kerrigan Perkins ; Stacy Postma ; Lauren Pratscher ; Elizabeth B Rand ; Regina K Rowe ; Danielle Schultz ; Katherine Sear ; Megan L Sell ; Tanvi Sharma ; Janis Stoll ; Mychoua Vang ; Dominique Villarin ; Carly Weaver ; Phoebe Wood ; Olivia Woodford-Berry ; George Yanni ; Lara A Danziger-Isakov

Importance:

Live vaccines (measles-mumps-rubella [MMR] and varicella-zoster virus [VZV]) have not been recommended after solid organ transplant due to concern for inciting vaccine strain infection in an immunocompromised host. However, the rates of measles, mumps, and varicella are rising nationally and internationally, leaving susceptible immunocompromised children at risk for life-threating conditions.

Objective:

To determine the safety and immunogenicity of live vaccines in pediatric liver and kidney transplant recipients.

Design, Setting, and Participants:

This cohort study included select pediatric liver and kidney transplant recipients who had not completed their primary MMR and VZV vaccine series and/or who displayed nonprotective serum antibody levels at enrollment between January 1, 2002, and February 28, 2023. Eligibility for live vaccine was determined by individual US pediatric solid organ transplant center protocols.

Exposures:

Exposure was defined as receipt of a posttransplant live vaccine. Transplant recipients received 1 to 3 doses of MMR vaccine and/or 1 to 3 doses of VZV vaccine.

Main Outcome and Measure:

Safety data were collected following each vaccination, and antibody levels were obtained at 0 to 3 months and 1 year following vaccination. Comparisons were performed using Mann-Whitney U test, and factors associated with development of postvaccination protective antibodies were explored using univariate analysis.

Results:

The cohort included 281 children (270 [96%] liver, 9 [3%] kidney, 2 [1%] liver-kidney recipients) from 18 centers. The median time from transplant to enrollment was 6.3 years (IQR, 3.4-11.1 years). The median age at first posttransplant vaccine was 8.9 years (IQR, 4.7-13.8 years). A total of 202 of 275 (73%) children were receiving low-level monotherapy immunosuppression at the time of vaccination. The majority of children developed protective antibodies following vaccination (107 of 149 [72%] varicella, 130 of 152 [86%] measles, 100 of 120 [83%] mumps, and 124 of 125 [99%] rubella). One year post vaccination, the majority of children who initially mounted protective antibodies maintained this protection (34 of 44 [77%] varicella, 45 of 49 [92%] measles, 35 of 42 [83%] mumps, 51 of 54 [94%] rubella). Five children developed clinical varicella, all of which resolved within 1 week. There were no cases of measles or rubella and no episodes of graft rejection within 1 month of vaccination. There was no association between antibody response and immunosuppression level at the time of vaccination.

Conclusions and Relevance:

The findings suggest that live vaccinations may be safe and immunogenic after solid organ transplant in select pediatric recipients and can offer protection against circulating measles, mumps, and varicella.

2023-08-19·Pediatric dermatology

Intralesional measles, mumps, and rubella vaccine after failure of intralesional Candida antigen for the treatment of recalcitrant pediatric warts.

Article

作者: Caden M Ulschmid ; Jay Patel ; Amy Y Pan ; Melodee Liegl ; Kristen E Holland

Numerous studies have investigated the efficacy of intralesional immunotherapy for warts, but there are a lack of studies investigating the efficacy of alternative intralesional immunotherapies following failure of initial intralesional immunotherapy. In this retrospective study, we aimed to investigate the efficacy of intralesional measles, mumps, and rubella vaccine for the treatment of pediatric warts following failure of intralesional therapy with Candida antigen. Following intralesional measles, mumps, and rubella vaccine administration, 8/51 (15.5%) patients had complete resolution of their warts, 6/51 (12%) had near complete resolution, 19/51 (37%) had partial improvement, 12/51 (23.5%) had no change, and 6/51 (12%) had worsening. Although limited by retrospective nature and low sample size, our results demonstrate that intralesional immunotherapy with measles, mumps, and rubella vaccine provides an alternative therapeutic option for the treatment of recalcitrant pediatric warts in patients who fail to respond to intralesional Candida antigen.

9

项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的新闻（医药）

2024-04-05

·Pharmaceutical Technology

England’s MMR vaccinations up 23% following NHS initiative

Vaccinations were up four fold in those aged five to 25 years old. Image credit: Shutterstock/didesign021. England’s NHS is calling its recent campaign to boost vaccination rates a success amidst a surge in measles, mumps , and rubella (MMR) cases. Latest data released by the health service shows that there were 23% more vaccinations in the first quarter of 2024 compared to the same time last year. A total of 360,964 jabs were delivered between January and March this year, compared to 293,847 in 2023. The biggest jump was seen in those aged five to 25 years old, with vaccinations up four-fold in that group between 2024 and 2023. In January, the UK Health Security Agency (UKHSA) declared a national incident following a surge in measles outbreaks across Britain. The highly contagious measles virus can cause serious illness and, in some cases, even death, in children and adults. It is also dangerous if caught during pregnancy, potentially resulting in stillbirth, miscarriage, and low birth weight. In the same month, the NHS started contacting millions of patients and carers in England to book their children in for a catch-up vaccine with a GP. The campaign also targeted those in the 11 to 25 year-age group in areas with low vaccine uptake rates such as London and the West Midlands. See Also: Touchlight joins forces with University of Liverpool for NSCLC vaccine Zoetis gets grant for recombinant viral vectors for multivalent pathogen protection in vaccines At the time, the NHS said its figures indicated that more than 3.4 million children under 16 years of age were unprotected against the three infectious diseases. There have been 934 confirmed cases of measles in England since the beginning of October last year, according to data from the UKSHA. The West Midlands accounted for around half of the cases seen since January. UKSHA head of immunisation Dr Mary Ramsay said: “The big increase in people, especially children, getting their MMR vaccine following our recent marketing campaign on missed immunisations is fantastic to see.” The NHS uses MSD’s M-M-RVaxPro and GSK ’s Priorix for MMR vaccines. The shots were approved for use in the UK in 1997 and 2006, respectively. They are recommended for all babies and young children, with adults able to receive one if unvaccinated. Two doses of the vaccines are required, resulting in lifelong protection with high efficacy against the three viruses which are easily spread between unvaccinated people. The World Health Organization (WHO) has said 95% vaccine coverage would eliminate measles in a population completely. The US has also seen a surge in measles cases , with the Centers for Disease Control and Prevention (CDC) reporting 97 cases in 2024 so far. Over half of the patients diagnosed with the virus were hospitalised. The CDC issued a health alert urging travellers, especially children, to get vaccinated. A statement from the American Medical Association echoed the call for vaccinations. The US also uses MSD’s M-M-R II and GSK’s Priorix.

疫苗上市批准

2024-03-21

·GlobeNewswire-Health Care

Rate of national measles cases highlights importance of vaccination

JEFFERSON CITY, Mo., March 21, 2024 (GLOBE NEWSWIRE) -- As vaccine uptake continues to decrease, measles cases or outbreaks have emerged in several states, including Missouri earlier this year. Nationally, the total number of measles cases has already reached the level that occurred during the entire year of 2023. With cases reported across the country, the Missouri Department of Health & Senior Services (DHSS) recommends parents and guardians check their child’s vaccination records to make sure they have received the measles, mumps and rubella (MMR) vaccine. This vaccine has been used in the United States since the 1970s and is a safe and effective way to protect children from measles. To be fully immunized, children are recommended to receive two doses of the MMR vaccine, with the first dose between ages 12-15 months and the second dose between ages 4-6 years old. Infants as young as 6 months can receive the first dose if traveling to areas where the measles infection rate is high. Families should consult their health care provider to discuss appropriate vaccine options for their children. Herd immunity, achieved through a measles vaccination rate of 95% or more, is crucial for preventing disease outbreaks in the community and protecting vulnerable populations who cannot receive vaccines. “Achieving this level of vaccination creates a barrier that limits the spread of infectious disease within a community, safeguarding those who are unable to be vaccinated due to their age or compromised immune systems,” said Dr. George Turabelidze, state epidemiologist with DHSS. Statewide, the MMR vaccination rate among kindergarteners has dropped steadily from 95.4% in the 2016-2017 school year to 90.5% at the start of the 2023-2024 school year, according to preliminary data reported by Missouri school districts. Religious (non-medical) exemptions have simultaneously increased from 1.9% to 3.5%. The measles vaccine, given as part of the MMR (measles, mumps and rubella) vaccine, is extremely effective, giving those vaccinated with just one dose 93% protection against measles infection. Both doses of the vaccine provide individuals with a 97% protection rate throughout their lifetime. Measles is a highly contagious and serious disease, especially serious for children under age five and those who are immunocompromised. Common symptoms include a rash that starts as flat red spots on the head and spreads to other parts of the body, high fever, cough, runny nose, red and watery eyes, and tiny white spots inside the mouth. But in some instances, individuals with measles will develop brain infection, which can lead to brain damage, and for some, the disease is fatal even with the best care. The virus spreads through coughing and sneezing and can live for up to two hours in an airspace after an infected person leaves an area. A person can spread measles without knowing they are infected. If not treated, complications can grow in severity. Most health insurance plans cover vaccines, but individuals should check with their insurance provider to verify coverage. For those without insurance, the Vaccines for Children Program, funded by the Centers for Disease Control and Prevention (CDC), provides free vaccines to children who qualify. Additionally, most local public health agencies throughout the state of Missouri offer vaccinations at affordable rates. To find a local public health agency near you and schedule an appointment, visit the Local Public Health Agency Directory. Mission of the Missouri Department of Health and Senior Services (DHSS): To promote health and safety through prevention, collaboration, education, innovation and response. MEDIA CONTACT:Lisa Cox (573-751-6062)Missouri Department of Health and Senior ServicesMedia Inquiry Form

疫苗

2024-02-01

·医药魔方

默沙东2023年财报：K药250亿美元登顶“药王”宝座，HPV疫苗近90亿美元

2月1日，默沙东公布2023年业绩，全年营收601.15亿美元，同比增长1%，扣除新冠口服药Lagevrio（莫诺拉韦）影响后，同比增长9%。默沙东制药业务收入535.83亿美元，同比增长3%，其中，中国区收入67.1亿美元，占据默沙东全球市场12.5%的份额，同比增长32%。王牌品种Keytruda（帕博利珠单抗）迎来其历史性高光时刻，全年营收250.11亿美元，同比增长19%，荣登2023年“药王”宝座。主要得益于在全球早期癌症患者群体（包括TNBC和RCC）中的使用，以及在全球转移性癌症患者中持续的强劲需求。九价HPV疫苗Gardasil/Gardasil 9销售额达88.86亿美元（+29%）。这两款产品占据默沙东总收入的56.4%，也成就了默沙东在肿瘤和疫苗领域的行业领导者地位。肿瘤领域产品Welireg（HIF-2α抑制剂）和Reblozyl（罗特西普），抗巨细胞病毒感染药物Prevymis（来特莫韦），以及15价肺炎球菌疫苗Vaxneuvance（V114）的销售额均呈现双位数及以上增长，带来了可观的增量收入。2023年默沙东主要产品销售额（亿美元）Keytruda无疑是默沙东的荣耀，自上市以来在与O药的缠斗中，已经将对手远远甩在身后。与此同时，这款超级重磅药物也面临2028年专利悬崖危机。不过在今年的JPM大会上，默沙东首席执行官Rob Davis向外界传达了乐观的信号，他表示，“现阶段讨论的焦点无疑是Keytruda和2028，不过我们越来越不再关注2028年，这只是一个年份而已。”Rob Davis拥有如此底气也不足为奇，毕竟默沙东已经针对这一即将面临的挑战未雨绸缪，做出了充分的应对措施。2023年，默沙东针对Keytruda新开了多项联合治疗III期临床研究，其中包括与肿瘤mRNA疫苗V940（mRNA-4157）联合治疗非小细胞肺癌（NSCLC）的两项研究，以及与TROP2 ADC新药MK-2870（从科伦博泰引进）联合一线治疗NSCLC的关键III期研究。除了继续挖掘Keytruda与其他疗法联合的治疗潜力，默沙东还计划通过增补肿瘤产品管线进一步丰富产品群来应对肿瘤业务可能面临的收入下滑情况。LSD1抑制剂Bomedemstat、BTK抑制剂Nemtabrutinib以及CYP11A1抑制剂MK-5684均被推向了III期临床。另外，去年10月，默沙东还以高达220亿美元的总金额引进了第一三共3款ADC新药 patritumab deruxtecan（HER3-DXd）、ifinatamab deruxtecan（I-DXd）和raludotatug deruxtecan（R-DXd），其中patritumab deruxtecan上市申请已于2023年12月获得FDA优先审评，适应症为三线治疗EGFR突变NSCLC。今年，受益于ADC候选药物以及癌症疫苗，默沙东将其肿瘤学组合下一个十年预估值提升到了200亿美元以上。疫苗领域，宫颈癌疫苗Gardasil/ Gardasil 9贡献了最核心的份额，同比增长29%至88.86亿美元，这主要仍得益于中国市场的强劲需求。用于预防麻疹、腮腺炎或水痘的ProQuad/M-M-R II/Varivax系列疫苗的销售额稳健增长达到23.68亿美元，另一种针对婴幼儿轮状病毒感染疫苗RotaTeq的销售额为7.69亿美元。默沙东和辉瑞在肺炎球菌疫苗赛道上开展了一场持久拉锯战。2023年，23价肺炎球菌疫苗Pneumovax 23销售额持续大幅下滑仅为4.12亿美元，跌幅达32%，也是默沙东财报中销售额下跌最严重的产品之一。而辉瑞Prevnar系列产品2023年卖出了64.4亿美元的好成绩。不过，默沙东在肺炎球菌疫苗赛道仍然有赶超辉瑞之势，15价肺炎球菌疫苗Vaxneuvance（V114）已于2021年7月获批上市，2022年8月将适用人群覆盖至6周龄以上儿童，2023年的销售额是2022年的近4倍，已达到6.65亿美元；用于成人的21价肺炎球菌疫苗V116对标Prevnar 20，已于2023年12月向FDA递交了上市申请并被纳入优先审评，如果获得上市批准，V116将成为首个专为成人设计的肺炎球菌结合疫苗。此外，默沙东布局在心血管/代谢、神经和免疫疾病领域都有产品布局，每一个细分赛道中都有新生代产品即将进入收获期或进入后期开发阶段，有望进一步补强现有产品群。在Adempas（2.55亿美元，+7%）的基础上，肺动脉高压新药Sotatercept蓄势待发，其生物制品许可申请（BLA）已获FDA授予优先审评资格，PDUFA日期定为2024年3月26日。代谢领域两款治疗2型糖尿病的产品Januvia与Janumet市场份额进一步萎缩。不过，其在研GLP-1R/GCGR双靶点激动剂efinopegdutide用于治疗非酒精性脂肪性肝炎 (NASH)的IIa期临床研究已于去年6月公布了积极结果。刚过去的JPM大会上，Robert Davis表示正在寻求具有减肥以外益处的GLP-1靶向疗法，因为非减肥适应症的开发更容易获得报销。心血管领域，口服PCSK9抑制剂MK-0616被寄予厚望，去年8月，默沙东新开了MK-0616治疗成人高胆固醇血症的大型III期CORALreef研究，该项目将在三项全球性研究中招募约17000名受试者，研究结果颇受期待。2023年，默沙东研发投入高达305.31亿美元，相当于将2023年收入的一半用于研发，其中仅收购与剥离造成的相关成本高达81.9亿美元。而其2022年的研发投入仅为135.48亿美元。仅在2023年，默沙东共启动了20多个III期研究项目。其中包括8款新的资产首次于2023年进入III期阶段。足以看出其在新药研发过程中重金投入的魄力。默沙东表示，今年计划开展更多临床试验。与此同时，Rob Davis表示，该公司正在寻找更多的中型交易。默沙东也对2024年业绩做了展望，预计全年收入将达到626-642亿美元。推荐阅读强生2023年财报出炉！乌司奴单抗超108亿美元，达雷妥尤单抗逼近百亿美元赛诺菲2023年财报：度普利尤单抗117亿美元，已在中美欧申报COPD适应症罗氏2023年财报：眼科双抗上市两年突破26亿美元，中国区收入60亿美元诺和诺德2023年财报：司美格鲁肽大卖212亿美元，Wegovy增长407%诺华2023年财报：Entresto销售额破60亿美元，中国区业绩增长17%GSK RSV疫苗销售额破十亿美元，继续领先辉瑞辉瑞2023年财报：营收585亿美元，RSV疫苗收入8.9亿美元翻倍增长！Enhertu 2023年全球销售25亿美元Copyright © 2024 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

疫苗财报临床3期信使RNA优先审批

100 项与 Measles, mumps and rubella vaccine(Merck Sharp & Dohme) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BD52	-

研发状态

适应症	最高研发状态	国家/地区	公司
腮腺炎	批准上市	欧盟更多	Merck Sharp & Dohme BV 更多
风疹	批准上市	列支敦士登更多	Merck Sharp & Dohme BV 更多
麻疹	批准上市	列支敦士登更多	Merck Sharp & Dohme BV 更多
水痘	终止	-	Merck Sharp & Dohme Corp. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00432523 (Pubmed \| BMC Med)	临床3期	腮腺炎 \| 麻疹 \| 水痘	-	M-M-RvaxPro intramuscular	廠艱繭繭選膚夢鬱糧鏇(獵製淵鹹淵積鑰觸願鑰) = 鹹夢選膚醖憲醖選範齋壓選憲遞簾衊願鏇範顧 (憲繭鹹廠繭鹽鬱顧膚膚 )	-	2009-04-14
NCT03239873 (CTgov)	临床3期	水痘	600	VARIVAX PE34+M-M-R II (VARIVAX PE34 + M-M-R II)	餘繭壓選積夢鬱鬱艱鹹(願鏇選築鑰顧鹹範願餘) = 廠衊醖積衊醖製顧蓋鏇鹹觸獵獵網窪醖蓋齋衊 (鏇衊壓簾糧獵艱衊膚淵, 構觸壓鬱鏇齋鬱顧繭夢 ~ 遞蓋鏇簾衊築願壓選膚) 更多	-	2019-08-26
				M-M-R® II vaccine (VARIVAX (2016 CP) + M-M-R II)	餘繭壓選積夢鬱鬱艱鹹(願鏇選築鑰顧鹹範願餘) = 襯網鑰廠鏇築衊遞蓋選鹹觸獵獵網窪醖蓋齋衊 (鏇衊壓簾糧獵艱衊膚淵, 餘艱餘壓餘夢糧簾範鏇 ~ 構憲製齋鬱鹽鑰鏇衊範) 更多
NCT00148941 (CTgov)	临床3期	白喉 \| 百日咳 \| 破伤风	4,209	SB213503 lot 1+M-M-R II (SB213503 Lot 1 + M-M-R Group)	餘蓋範選願鏇蓋鑰範膚(夢憲鑰膚鹽糧網範築鹽): GMC ratio = 0.970 (95% CI, 0.871 ~ 1.080); GMC ratio = 0.975 (95% CI, 0.866 ~ 1.097) 更多	-	2020-02-05
				SB213503 lot 2+M-M-R II (SB213503 Lot 2 + M-M-R Group)
P03.243 (AAN2012)	N/A	急性播散性脑脊髓炎	722	Hemophilus influenza b vaccine	(鏇積選積鏇壓壓廠觸繭) = 壓廠築廠糧衊構選齋願鑰鑰鏇簾鑰衊壓鹽鬱膚 (製糧餘願獵積積蓋鏇簾 )	不佳	2012-04-23
				Hepatitis B vaccine	(鏇積選積鏇壓壓廠觸繭) = 壓鹹廠憲繭製齋鏇廠膚鑰鑰鏇簾鑰衊壓鹽鬱膚 (製糧餘願獵積積蓋鏇簾 )
NCT01000311 (CTgov)	临床3期	脑膜炎球菌感染	529	PCV+HBV+MenACWY-CRM+MMR (MenACWY-CRM + Routine Vaccines)	膚醖積鏇憲簾襯糧鏇願(窪鑰願選鑰鹹鏇壓窪窪) = 構遞製鹽選範襯選餘膚繭積構衊醖淵襯鹽鹽壓 (簾範製艱衊蓋鏇蓋簾艱, 選積遞壓遞鏇齋蓋構遞 ~ 製夢簾鏇齋獵簾簾窪廠) 更多	-	2014-03-26
				PCV+HBV+MMR (Routine Vaccines)	膚醖積鏇憲簾襯糧鏇願(窪鑰願選鑰鹹鏇壓窪窪) = 築蓋夢鑰網憲鑰鏇願鹽繭積構衊醖淵襯鹽鹽壓 (簾範製艱衊蓋鏇蓋簾艱, 願醖積積鏇鑰鏇艱壓願 ~ 網襯願製蓋襯襯齋鏇構) 更多
NCT03893448 (CTgov)	临床3期	肺炎 \| 肺炎球菌感染 \| 18型肌张力障碍	1,720	HIBERIX™+Pentacel™+Varivax™+RECOMBIVAX HB™+VAQTA™+RotaTeq™+V114+MMR II™ (V114)	(蓋繭衊淵積簾鹽鬱醖廠): Percentage Point Difference = -4.8 (95.0% CI, -9.3 ~ -0.2); Percentage Point Difference = -0.4 (95.0% CI, -4.6 ~ 3.7); Percentage Point Difference = 2.9 (95.0% CI, -1.9 ~ 7.6); Percentage Point Difference = 2.4 (95.0% CI, -1.7 ~ 6.5) 更多	-	2022-03-25
				HIBERIX™+Pentacel™+Varivax™+RECOMBIVAX HB™+VAQTA™+RotaTeq™+Prevnar 13™+MMR II™ (Prevnar 13™)
NCT01553279 (CTgov)	临床3期	细菌感染 \| 病毒感染 \| 脑膜炎	284	Hib-MCC+V419+PREVNAR 13®+MCC-TT+MMR Vaccine (V419 and MCC-TT)	願憲願積餘餘積襯積餘(簾鏇構糧顧簾鹹蓋簾製) = 壓築鹽範遞淵廠顧選選窪鹹醖醖襯憲衊範壓願 (積觸鏇鹽襯範齋獵網醖, 願醖蓋願鬱範獵積觸餘 ~ 觸鬱壓齋醖夢鏇襯鏇衊) 更多	-	2019-03-28
				Hib-MCC+MCC-CRM+V419+PREVNAR 13®+MMR Vaccine (V419 and MCC-CRM)	願憲願積餘餘積襯積餘(簾鏇構糧顧簾鹹蓋簾製) = 網網範夢網蓋齋鏇襯艱窪鹹醖醖襯憲衊範壓願 (積觸鏇鹽襯範齋獵網醖, 鹽顧壓憲顧鏇夢醖壓構 ~ 醖衊觸衊艱鹽糧範鏇獵) 更多
NCT00289783 (CTgov)	临床3期	嗜血杆菌感染 \| 脑膜炎	4,441	GSK Biologicals' Haemophilus influenzae type b+Varivax+Prevnar+Pediarix+M-M-R II (Menhibrix A Group)	網鬱積獵築鹹選製蓋鹽(窪鬱窪願積鬱蓋餘顧鏇) = 憲廠觸餘製鹹醖繭獵糧築築願膚鑰窪鹹繭範襯 (繭製膚壓廠夢齋齋鹹餘, 製積艱築製遞鹹鏇壓窪 ~ 鏇鹽範鹽鹽廠窪鑰鑰餘) 更多	-	2012-08-06
				GSK Biologicals' Haemophilus influenzae type b+Varivax+Prevnar+Pediarix+M-M-R II (Menhibrix B Group)	網鬱積獵築鹹選製蓋鹽(窪鬱窪願積鬱蓋餘顧鏇) = 觸蓋繭蓋壓鏇餘願範窪築築願膚鑰窪鹹繭範襯 (繭製膚壓廠夢齋齋鹹餘, 鹽選襯獵獵繭鏇築鏇憲 ~ 夢鬱構願窪醖願簾選鏇) 更多
NCT02062502 (CTgov)	临床3期	水痘	611	VARIVAX™ 2007 process+M-M-R II™	製憲憲廠繭製齋鑰鑰願(艱選齋艱構襯窪憲獵蓋) = 簾齋蓋築艱網鹽淵鬱築餘願獵鏇顧觸夢遞繭襯 (遞艱築艱艱觸憲網夢觸, 膚鹽艱襯膚製顧膚製鏇 ~ 繭鏇選鹹築齋餘範窪艱) 更多	-	2016-03-01
NCT04016714 (CTgov)	临床3期	肺炎球菌感染	1,191	VARIVAX™+Vaxelis™+V114+M-M-R®II (V114)	製夢窪糧選鬱網鏇艱選(鏇艱餘網獵膚廠願壓鏇): Difference in percentage vs Prevenar 13™ = -5.5 (95% CI, -11.0 ~ 0.0); Difference in percentage vs Prevenar 13™ = -2.1 (95% CI, -7.7 ~ 3.5); Difference in percentage vs Prevenar 13™ = 3.4 (95% CI, -2.1 ~ 8.9); Difference in percentage vs Prevenar 13™ = 2.3 (95% CI, -3.4 ~ 7.9) 更多	-	2022-12-01
				VARIVAX™+Vaxelis™+Prevenar 13™+M-M-R®II (Prevenar 13™)